0000899243-22-036575.txt : 20221121 0000899243-22-036575.hdr.sgml : 20221121 20221121190442 ACCESSION NUMBER: 0000899243-22-036575 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221117 FILED AS OF DATE: 20221121 DATE AS OF CHANGE: 20221121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HIGGINS JOHN L CENTRAL INDEX KEY: 0001208906 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 221407095 MAIL ADDRESS: STREET 1: 11119 NORTH TORREY PINES ROAD, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-11-17 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001208906 HIGGINS JOHN L 3911 SORRENTO VALLEY BOULEVARD, SUITE 110 SAN DIEGO CA 92121 1 1 0 0 Chief Executive Officer Common Stock 2022-11-17 4 S 0 10000 78.3173 D 416731 D Common Stock 2022-11-18 4 M 0 10000 12.78 A 426731 D Non-Qualified Stock Option (right to buy) 12.78 2022-11-18 4 M 0 10000 0.00 D 2023-02-15 Common Stock 10000 40335 D The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 22, 2022, in accordance with Rule 10b5-1. Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The original date of grant was 02/15/13. /s/ Andrew Reardon, Attorney-in-Fact for John L. Higgins 2022-11-21